Amgen’s IMDELLTRA Gets Reduced FDA Monitoring Time

Thousand Oaks, California, U.S., September 14, 2026

FDA Updates IMDELLTRA Monitoring Requirements

The revised prescribing information represents a significant regulatory and treatment-administration update for IMDELLTRA. Following the first two doses, the recommended monitoring schedule remains unchanged: patients should receive 6 to 8 hours of monitoring after the third dose, administered on Cycle 1 Day 15, and throughout Cycle 2. Monitoring then decreases to 3 to 4 hours for Cycles 3 and 4, followed by 2 hours for Cycle 5 and subsequent doses. Although the required onsite monitoring period has been substantially shortened, patients receiving the first and second doses are still recommended to remain within one hour of an appropriate healthcare setting for 48 hours from the beginning of each infusion and should be accompanied by a caregiver. Follow-up assessments, including vital signs, are required on Cycle 1 Day 2 and Day 9. These measures are intended to support early identification and management of adverse reactions that may occur after patients leave the infusion facility. The updated requirement could have implications for community oncology care, where many patients receive cancer treatment closer to home. Amgen said the reduction in monitoring time may help make administration of IMDELLTRA more feasible in community settings and potentially reduce the burden associated with extended stays at healthcare facilities.

IMDELLTRA Uses DLL3-Directed T-Cell Engagement

IMDELLTRA (tarlatamab-dlle) is a targeted immunotherapy designed to bind simultaneously to DLL3 on tumor cells and CD3 on T cells. This dual-targeting mechanism brings T cells into close proximity with DLL3-expressing cancer cells, promoting formation of a cytolytic synapse and subsequent T-cell-mediated tumor-cell killing. DLL3 is expressed on the surface of a large proportion of SCLC tumors while showing limited expression in healthy tissues, making it an important therapeutic target in the disease. IMDELLTRA is currently indicated in the United States for the treatment of adult patients with extensive-stage small cell lung cancer whose disease has progressed on or after platinum-based chemotherapy. The treatment is administered intravenously using a step-up dosing schedule, which is intended to reduce the incidence and severity of cytokine release syndrome (CRS). The FDA’s monitoring update does not eliminate the important safety requirements associated with IMDELLTRA. The prescribing information continues to carry boxed warnings for cytokine release syndrome and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS). Healthcare professionals must administer the therapy in an appropriate facility equipped to recognize and manage serious reactions.

Safety Measures Remain Central to Treatment

The updated monitoring approach reflects continued attention to the timing and management of treatment-related adverse events. In the pooled safety population, CRS occurred in 57% of patients, with most events being Grade 1 or Grade 2. CRS was more frequently observed following the first two doses, supporting the continued requirement for close monitoring during these initial administrations. The median time to onset of CRS from the most recent dose was 16 hours, although the reported range extended from the start of infusion to 15 days. Neurologic toxicity also remains an important safety consideration. Neurologic toxicity occurred in 65% of patients in the pooled safety population, with Grade 3 or higher events reported in 7%. ICANS occurred in 10% of patients, demonstrating why patients and caregivers must continue to receive education about potential symptoms and the need for prompt medical attention. The FDA-approved reduction in monitoring time therefore represents an important regulatory milestone for IMDELLTRA administration, rather than a removal of safety precautions. By shortening the required initial onsite monitoring period while maintaining next-day assessments and proximity requirements, the updated labeling could help reduce treatment burden while preserving safeguards for patients receiving this DLL3-directed cancer immunotherapy.

Source: Amgen press release